Merck, Portola enter worldwide license pact to develop & commercialize betrixaban for cardiovascular disease

Merck & Co, Inc and Portola Pharmaceuticals, Inc have signed an exclusive global collaboration and license agreement for the development and commercialization of betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in phase-II clinical development for the prevention of stroke in patients with atrial fibrillation (SPAF).

Comments

Post a Comment

Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Image
GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut    Vox Author of GOP Tax Plan Says Children's Health Insurance Program Is Held Up “Because We Don't Have Money ...    The Intercept Nevada wins short reprieve in child health care funds fight    Sacramento Bee Ben McAdams: Congress to Tiny Tim: 'No health insurance for you.'    Salt Lake Tribune Full coverage
Read more

Trump wants more mental health care; Alabama says it's trying

Image
Trump wants more mental health care; Alabama says it's trying    AL.com Budget undercuts Trump focus on mental health, school safety    Yahoo News Mental health awareness license plates offered by New York State DMV    Buffalo News Trump wants to 'tackle the difficult issue of mental health?' He should put his money where his mouth is.    Washington Post Full coverage
Read more